These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 22294238)

  • 21. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
    DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM
    Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD; Endicott JM; Loebel AD
    Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
    Citrome L
    Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
    Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M
    J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study.
    Cookson J; Keck PE; Ketter TA; Macfadden W
    Int Clin Psychopharmacol; 2007 Mar; 22(2):93-100. PubMed ID: 17293709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
    Heo JY; Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; Pisoni A; Papakostas GI
    J Psychiatr Res; 2015 Mar; 62():56-61. PubMed ID: 25659187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
    Papakostas GI; Vitolo OV; Ishak WW; Rapaport MH; Zajecka JM; Kinrys G; Mischoulon D; Lipkin SH; Hails KA; Abrams J; Ward SG; Meisner A; Schoenfeld DA; Shelton RC; Winokur A; Okasha MS; Bari MA; Fava M
    J Clin Psychiatry; 2012 Dec; 73(12):1541-7. PubMed ID: 23290327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term remission in schizophrenia as a combination of several outcome measures.
    Stratta P; Rossi A
    Psychiatry Res; 2013 Oct; 209(3):401-5. PubMed ID: 23684054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services.
    Pascual JC; Oller S; Soler J; Barrachina J; Alvarez E; Pérez V
    J Clin Psychiatry; 2004 Sep; 65(9):1281-2. PubMed ID: 15367057
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review.
    Shim IH; Bahk WM; Woo YS; Yoon BH
    Clin Psychopharmacol Neurosci; 2018 Nov; 16(4):376-382. PubMed ID: 30466209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials.
    Fornaro M; Stubbs B; De Berardis D; Perna G; Valchera A; Veronese N; Solmi M; Ganança L
    Int J Mol Sci; 2016 Feb; 17(2):241. PubMed ID: 26891297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials.
    Wang HR; Woo YS; Ahn HS; Ahn IM; Kim HJ; Bahk WM
    Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25770098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state.
    Pae CU; Patkar AA; Gilmer W; Holtzman N; Thommi SB; Ghaemi SN
    Pharmacopsychiatry; 2012 Jun; 45(4):152-5. PubMed ID: 22294238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.